Thyrocare Technologies Limited will host an earnings conference call on July 23, 2026, at 6:00 PM IST to discuss its unaudited financial results for the quarter ended June 30, 2026. The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The call provides an opportunity for analysts and investors to interact with the company's senior management regarding the performance for Q1FY27.

The discussion will be led by key executives including Mr. Rahul Guha, Chairman, MD & CEO, and Mr. Vikram Gupta, CFO. Other speakers include Mr. Rajdeep Panwar, CCO, Dr. Ramesh Kinha, COO, and Mr. Preet Joshi, Manager - Strategy & Investor Relations.

Participants can join the conference call via universal access numbers or through webcast registration. The management will address queries related to the financial results and operational highlights for the period.

Conference Call Details

Thyrocare Technologies Limited reported a consolidated profit of ₹162.85 crore for the financial year ended March 31, 2026, reflecting a 79% increase year-on-year, at its 26th Annual General Meeting (AGM) held on June 30, 2026. Consolidated revenue grew by 21% to ₹829.04 crore, driven by the processing of over 210 million tests during the year. The Independent Auditors’ Reports on both Standalone and Consolidated Financial Statements contained no qualifications, reservations, or adverse remarks.

The meeting, held at the Corporate Office in Navi Mumbai, saw the participation of 66 shareholders holding 61.10% of the total paid-up equity share capital. Mr. Rahul Franklin Guha, Chairman, Managing Director and Chief Executive Officer, chaired the proceedings. Shareholders approved the adoption of the audited standalone and consolidated financial statements for the year ended March 31, 2026.

Financial and Operational Highlights

Thyrocare served 19.2 million patients across India during the year, with a network spanning over 5,400 pin codes and supported by more than 10,800 quarterly active franchisees. The Chairman noted that 96% of samples were processed through NABL accredited owned laboratories, with an average turnaround time of 3.4 hours from sample receipt.

Key Governance Approvals

Shareholders declared a final dividend of ₹7.00 per equity share and confirmed the payment of an interim dividend of ₹7.00 per equity share (pre-bonus issue), equivalent to ₹2.33 per equity share post bonus adjustment, on shares with a face value of ₹10 each. The AGM approved the re-appointment of Mr. Rahul Franklin Guha as Chairman, Managing Director and Chief Executive Officer effective May 04, 2027, along with his remuneration.

M/s. Price Waterhouse Chartered Accountants LLP was appointed as the Statutory Auditors for a first term of five consecutive years. Additionally, shareholders approved the appointment of Mr. Gaurav Verma and Mr. Uday Patel Kadam as Directors (Non-Executive and Non-Independent) of the company with effect from May 08, 2026.

MOA Amendment Details

The amendment to the Memorandum of Association included the substitution of the heading of Clause III(A) to "THE OBJECTS TO BE PURSUED BY THE COMPANY ARE" and the addition of Sub clause 1B under Clause III(A)(1). This new sub-clause authorizes the company to carry on the business of establishing, setting up, acquiring, operating, managing or administering diagnostic facilities, including clinical laboratories and research centres. It also permits the development of healthcare and diagnostic data-driven digital platforms.

Further changes included the substitution of the heading of Clause III(B) to "Matters which are necessary for furtherance of the objects specified in Clause III(A) are:" and the deletion of the header of Clause III(C) regarding "Other Objects" to align with the Companies Act, 2013. Clause IV was substituted to specify that the liability of members is limited to the amount unpaid on the shares held by them. All references to the Companies Act, 1956 were replaced with corresponding provisions of the Companies Act, 2013.